- 300 patients enrolled in the study, including patients with and without the cognitive biomarker –
- On track to report topline data in October 2024 –
- Alto to host investor day focused on ALTO-100 on September 9, 2024 –
Alto Neuroscience Completes Enrollment In ALTO-100 Phase 2b Study, Topline Results Expected In October
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.